サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：ゲノムバイオマーカーの世界市場-2022-2029
市場調査レポート
商品コード
1129276

ゲノムバイオマーカーの世界市場-2022-2029

Global Genomic Biomarker Market - 2022-2029
出版日: | 発行: DataM Intelligence | ページ情報: 英文 200 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
ゲノムバイオマーカーの世界市場-2022-2029
出版日: 2022年09月29日
発行: DataM Intelligence
ページ情報: 英文 200 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場力学

政府当局によるヘルスケア産業への投資の拡大が、市場成長の原動力になると予想されます。

メディケア＆メディケイドサービスセンター（CMS）の推計によると、米国の国民医療費は2018年から2027年にかけて年平均5.5%の割合で増加し、その時期には約6兆米ドル規模に達すると予測されています。さらに、2020年5月には、分子診断技術を開発するドイツのQiagen社が、様々な種類のがんにおけるゲノム解析のための最先端技術の導入を発表しています。最先端のQIAseq汎癌マルチモーダルパネルは、たった1回のサンプル入力で、腫瘍の変異負荷やマイクロサテライト不安定性の状態を評価するための600以上のDNAおよびRNAバイオマーカーを発見し、濃縮することができます。したがって、上記の記述から、予測期間中に市場が牽引されることが予想されます。

制約事項

ゲノムバイオマーカーのコストが高いこと、政府の規制が厳しいこと、遺伝子バイオマーカーのみに基づく診断方法の信頼性が低いこと。これらは、予測期間中に市場が阻害されると予想されるいくつかの要因です。

産業分析

ゲノムバイオマーカー市場は、サプライチェーン分析、価格分析など、様々な産業要因に基づいた市場の詳細な分析を提供します。

COVID-19の影響分析

COVID-19のパンデミックは、ヘルスケアシステムと市場に中程度の影響を与えています。SARS-CoV-2はコロナウイルス科という共通の特性により、構造的特徴や侵入メカニズムが明らかになっています。一方、急激な変異原性により、様々な繁殖率や感染力を持つ新規株が形成され、病気の性質や重症度に影響を及ぼす可能性があります。COVID-19の強度や結果、感染しやすさは、いずれも宿主に関連した要因に影響されると考えられます。スパイクタンパク質の変異が、この株の細胞感染能力やACE2受容体への付着能力に与える影響は、バイオインフォマティクスを用いて予測することができます。

さらに、SARS-CoV-2はいくつかの転写因子や腫瘍抑制遺伝子を標的とし、多くの宿主遺伝子の発現や細胞シグナル伝達に影響を与える可能性があります。また、内在性のmiRNAとそのウイルスRNAを利用することで、宿主細胞におけるRNAの発現を阻害する可能性もあります。ある種のヒトmiRNAは、ウイルスRNAの様々なコーディング領域や非コーディング領域と結合し、二重鎖を形成することが明らかにされています。また、ウイルスの侵入や複製、分子損傷応答や炎症経路に関与するヒト遺伝子の多型は、疾患の予後や経過に影響を与える可能性があります。これらの多型遺伝子にコードされるタンパク質は、Gene Ontology解析によると、防御反応の制御に大きく関係していることが判明しました。したがって、ウイルスと宿主に関連する遺伝的・エピジェネティックなバイオマーカーは、病気の進行や治療効果の予測に役立つと考えられます。

一方、パンデミックはサプライチェーンとプロセスを中断させる。多くの企業は、製品の入手可能性を確保し、サプライチェーンを保護するために、他の地域へと変化していくでしょう。このように、上記の記述から、市場は影響を受けましたが、経済活動の再開に伴い、急速に牽引されると予想されます。

本レポートは、約45以上の市場データ表、40以上の図、200ページへのアクセスを提供するものです。

目次

第1章 調査手法と調査範囲

  • 調査手法
  • 調査目的および調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

第4章 市場の力学

  • 市場影響要因
    • 促進要因
      • 政府当局別ヘルスケア産業への投資の拡大が、市場成長の原動力になると予想されます。
    • 抑制要因
      • ゲノムバイオマーカーのコストが高いことが市場成長の阻害要因になると予想されます。
    • 機会
    • 影響分析

第5章 産業分析

  • サプライチェーン分析
  • 価格設定分析

第6章 COVID-19の分析

  • COVID-19の市場分析
    • COVID-19以前の市場シナリオ
    • COVID-19の現在の市場シナリオ
    • COVID-19の後、または将来のシナリオ
  • COVID-19の中での価格変動
  • 需要-供給スペクトラム
  • パンデミック時の市場に関連する政府の取り組み
  • メーカーの戦略的な取り組み
  • まとめ

第7章 タイプ別

  • 予測型バイオマーカー
  • 予後バイオマーカー

第8章 バリデーション別

  • 解析的バリデーション
  • 臨床的バリデーション
  • 臨床的有用性
  • その他

第9章 適応症別

  • オンコロジー
  • 循環器系疾患
  • 神経系疾患
  • 腎臓疾患
  • その他

第10章 エンドユーザー別

  • 病院
  • 診断センター
  • 調査研究機関
  • その他

第11章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他の南米地域
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ地域

第12章 競合情勢

  • 主な展開と戦略
  • 企業シェア分析
  • 製品ベンチマーク
  • 注目の主要企業リスト

第13章 企業プロファイル

  • Thermo Fisher Scientific
    • 企業概要
    • 製品ポートフォリオと説明
    • 主なハイライト
    • 財務概要
  • Bio-Rad Laboratories, Inc.
  • Myriad Genetics, Inc.
  • QIAGEN
  • Eurofins Scientific
  • Exact Sciences
  • Sema4
  • Creative Diagnostics
  • Centogene N.V.
  • Quanterix

第14章 ゲノムバイオマーカーの世界市場-DataM

目次
Product Code: DMOT5830

Market Overview

Genomic Biomarker Market size was valued US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of 15% during the forecast period (2022-2029).

Genomic biomarkers are signs that assess for clinical diagnosis based on gene expression, gene mutation, gene regulation, and other gene features. Neurological, oncological, and cardiovascular illnesses can all be detected using genomic biomarkers. Genomic biomarkers aid in the early diagnosis of disease, tracking disease progression and assessing the biological response to treatment or therapy. Genomic biomarkers can be utilized as a diagnostic indicator on their own or in conjunction with other biomarkers such as protein biomarkers. mRNA, miRNA, cell-free DNA, long coding RNA, and other genomic biomarkers are used in clinical diagnosis.

Market Dynamics

The growing investment by government authorities in the healthcare industry is expected to drive market growth.

The Centers for Medicare & Medicaid Services (CMS) estimates that national health spending in the United States increased at an average rate of 5.5 percent per year from 2018 to 2027 and is projected to reach around USD 6.0 trillion by that time. Moreover, in May 2020, Qiagen, a German company that develops molecular diagnostics technology, announced the introduction of cutting-edge technologies for genomic analysis in various cancer kinds. The cutting-edge QIAseq pan-cancer multimodal panel with just one sample input can discover and enrich more than 600 DNA and RNA biomarkers for evaluating tumor mutational load and microsatellite instability status. Thus, from the above statements, the market is expected to drive in the forecast period.

Restraint:

High costs of the genomic biomarkers, stringent government restrictions, and diagnostic method based solely on genetic biomarkers is less reliable. These are some factors the market is expected to get hampered in the forecast period.

Industry Analysis

The genomic biomarker market provides in-depth analysis of the market based on various industry factors such as supply chain analysis, pricing analysis etc.

COVID-19 Impact Analysis

The COVID-19 pandemic has moderately impacted healthcare systems and the market. The structural characteristics and entrance mechanism of SARS-CoV-2 are clarified due to the shared characteristics of the coronavirus family. Rapid mutagenesis, on the other hand, causes the formation of novel strains that may have various rates of reproduction or infectiousness and may affect the nature and severity of the illness. The intensity and results of COVID-19 and the susceptibility to infection may all be influenced by host-related factors. The impact of spike protein mutations on the strain's ability to infect cells and attach to the ACE2 receptor can be predicted using bioinformatics.

Additionally, SARS-CoV-2 may target several transcription factors and tumor suppressor genes, impacting the expression of many host genes and cell signaling. By using endogenous miRNA and its viral RNA, the virus may also impede RNA expression in host cells. It is revealed that certain human miRNA may associate with various coding and non-coding regions of viral RNA to produce duplexes. Polymorphisms may also influence the prognosis and course of a disease in human genes involved in viral entry and replication, as well as in molecular damage response and inflammatory pathways. Proteins encoded by these polymorphic genes are highly related to the regulation of the defense response, according to a gene ontology analysis. Genetic and epigenetic biomarkers connected to the virus and host may therefore aid in predicting the progression of the disease and the effectiveness of treatment.

In contrast, the pandemic interrupts the supply chain and process. Many companies will vary to other geographic regions to ensure that products remain available and protect their supply chain. Thus, from the above statements, the market got affected, and it is expected to gain traction quickly with the resumption of economic activities.

Segment Analysis

Predictive Biomarkers segment is expected to hold the largest market share in genomic biomarker market

The predictive biomarkers segment is expected to dominate in 2021. The segment benefits because predictive biomarkers are baseline or pretreatment data that reveal whether patients are more or least likely to benefit from a certain treatment. A predictive biomarker is frequently chosen as a companion predictive biomarker in developing a specific therapeutic medication. As a typical oncology example, a biomarker that detects overexpression of the growth factor protein Her-2, which transmits growth signals to breast cancer cells, maybe a predictive biomarker for the administration of trastuzumab (Herceptin). This drug inhibits the effects of Her-2 on breast cancer patients. Therefore, it has increased the demand for predictive biomarkers. Thus, from the above statements, the market segment is expected to hold the largest market share in the forecast period.

Geographical Analysis

North America region holds the largest market share in the global genomic biomarker market

In 2021, North America accounted for the highest revenue share. The increasing prevalence of cancer and cardiovascular disease, advancements in the genomic biomarker, increasing adoption of genomic biomarkers in the early diagnosis of diseases, product launches by the key market players, and regulatory approvals in the region are some of the factors the market is expected to boost in the forecast period. For instance, according to the American Cancer Society, In 2020, an estimated 1.8 million new cancer cases and 606,520 cancer deaths in the United States will be diagnosed. In contrast, in 2021, an estimated 1.9 million new cancer cases will be diagnosed and 608,570 cancer deaths in the United States. Therefore, it has increased the adoption of genomic biomarkers in the early diagnosis of diseases.

Moreover, Clinical genomics delivery in everyday healthcare has been completed under Color Genomics' US program, the company announced in January 2020 in collaboration with NorthShore University HealthSystem. Additionally, the business supported Sanford's Imagenetics genomes program, which will improve clinical judgment. This project is also to blame for the region's widespread use of genetic biomarkers. Thus, from the above statements, the North American region is expected to hold the largest market share in the forecast period.

Competitive Landscape

Major key players in the genomic biomarker market are Thermo Fisher Scientific,Bio-Rad Laboratories, Inc., Myriad Genetics, Inc., QIAGEN, Eurofins Scientific, Exact Sciences, Sema4, Creative Diagnostics, Centogene N.V., Quanterix.

Bio-Rad Laboratories, Inc.:

Overview:

Bio-Rad Laboratories, Inc. is an American company that continues to produce innovative and useful products in the healthcare industry that assist life science researchers in accelerating the discovery process, and medical diagnostic labs obtain faster results. Bio-Rad's life science products include instruments, software, consumables, reagents, and content for cell biology, gene expression, protein purification, protein quantitation, drug discovery and manufacture, food safety, and science education. These products are based on technologies to separate, purify, identify, analyze, and amplify biological materials such as antibodies, proteins, nucleic acids, cells, and bacteria. Moreover, Bio-Rad's diagnostic products and systems use various technologies and provide clinical information in the blood transfusion, diabetes monitoring, autoimmune, and infectious disease testing markets. These products support diagnosing, monitoring, and treating diseases and other medical conditions.

Product Portfolio:

CFX Real-Time PCR Detection System: Powerful and flexible instruments with 2-5 color multiplexing to deliver sensitive, reliable detection of both single and multiplex real-time PCR reactions. High-throughput CFX Automation System can screen up to 84 plates in 24 hours.

The global genomic biomarker market report would provide an access to an approx. 45+market data table, 40+figures and 200pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The growing investment by government authorities in the healthcare industry is expected to drive market growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. High costs of the genomic biomarkers are expected to hamper the market growth.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Supply Chain Analysis
  • 5.2. Pricing Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type Segment
  • 7.2. Predictive Biomarkers*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Prognostic Biomarkers

8. By Validation

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Validation
    • 8.1.2. Market Attractiveness Index, By Validation Segment
  • 8.2. Analytical Validation*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Clinical Validation
  • 8.4. Clinical Utility
  • 8.5. Others

9. By Indication

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 9.1.2. Market Attractiveness Index, By Indication Segment
  • 9.2. Oncology*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Cardiovascular Diseases
  • 9.4. Neurological Diseases
  • 9.5. Renal Disorders
  • 9.6. Others

10. By End user

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.1.2. Market Attractiveness Index, By End user Segment
  • 10.2. Hospitals*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Diagnostic Centers
  • 10.4. Research Laboratories
  • 10.5. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Validation
    • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Validation
    • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Validation
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Validation
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Validation
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user

12. Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Product Benchmarking
  • 12.4. List of Key Companies to Watch

13. Company Profiles

  • 13.1. Thermo Fisher Scientific*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Bio-Rad Laboratories, Inc.
  • 13.3. Myriad Genetics, Inc.
  • 13.4. QIAGEN
  • 13.5. Eurofins Scientific
  • 13.6. Exact Sciences
  • 13.7. Sema4
  • 13.8. Creative Diagnostics
  • 13.9. Centogene N.V.
  • 13.10. Quanterix

LIST NOT EXHAUSTIVE

14. Global Genomic Biomarker Market - DataM

  • 14.1. Appendix
  • 14.2. About Us and Applications
  • 14.3. Contact Us